Back to top
more

Schrodinger (SDGR)

(Delayed Data from NSDQ)

$21.37 USD

21.37
508,121

-0.42 (-1.93%)

Updated Jul 19, 2024 04:00 PM ET

After-Market: $21.36 -0.01 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (74 out of 250)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Schrodinger, Inc. (SDGR) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Schrodinger (SDGR) delivered earnings and revenue surprises of 0% and 11.24%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Schrodinger, Inc. (SDGR) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Schrodinger, Inc. (SDGR) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Schrodinger, Inc. (SDGR) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Schrodinger, Inc. (SDGR) delivered earnings and revenue surprises of 27.27% and 4.73%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Countdown to Schrodinger, Inc. (SDGR) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS

by Zacks Equity Research

Besides Wall Street's top -and-bottom-line estimates for Schrodinger, Inc. (SDGR), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.

Compared to Estimates, Schrodinger, Inc. (SDGR) Q3 Earnings: A Look at Key Metrics

by Zacks Equity Research

Although the revenue and EPS for Schrodinger, Inc. (SDGR) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Schrodinger, Inc. (SDGR) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Schrodinger, Inc. (SDGR) delivered earnings and revenue surprises of 51.16% and 0.25%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Will Schrodinger, Inc. (SDGR) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Schrodinger, Inc. (SDGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tabula Rasa Healthcare (TRHC) Moves 6.3% Higher: Will This Strength Last?

by Zacks Equity Research

Tabula Rasa Healthcare (TRHC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Schrodinger, Inc. (SDGR) Surges 6.6%: Is This an Indication of Further Gains?

by Zacks Equity Research

Schrodinger, Inc. (SDGR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Schrodinger, Inc. (SDGR) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Schrodinger, Inc. (SDGR) delivered earnings and revenue surprises of -127.94% and 3.02%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Schrodinger, Inc. (SDGR) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Schrodinger, Inc. (SDGR) delivered earnings and revenue surprises of 22% and 16.74%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

10x Genomics (TXG) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

10x Genomics (TXG) delivered earnings and revenue surprises of 48.28% and 6.50%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Phreesia (PHR) Soars 6.1%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Phreesia (PHR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Schrodinger, Inc. (SDGR) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Schrodinger, Inc. (SDGR) delivered earnings and revenue surprises of 8.20% and 14.37%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Schrodinger, Inc. (SDGR) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Schrodinger, Inc. (SDGR) delivered earnings and revenue surprises of -1.64% and 2.88%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Schrodinger, Inc. (SDGR) Q2 Earnings Expected to Decline

by Zacks Equity Research

Schrodinger, Inc. (SDGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Schrodinger, Inc. (SDGR) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Schrodinger, Inc. (SDGR) delivered earnings and revenue surprises of 12.73% and 36.14%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Schrodinger, Inc. (SDGR) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Schrodinger, Inc. (SDGR) delivered earnings and revenue surprises of -13.16% and 25.36%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Pulmonx Corporation (LUNG) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Pulmonx Corporation (LUNG) delivered earnings and revenue surprises of 0% and 3.53%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Schrodinger, Inc. (SDGR) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Schrodinger, Inc. (SDGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Schrodinger, Inc. (SDGR) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Schrodinger, Inc. (SDGR) delivered earnings and revenue surprises of -25.64% and -9.82%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Schrodinger, Inc. (SDGR) Q3 Earnings Expected to Decline

by Zacks Equity Research

Schrodinger, Inc. (SDGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Schrodinger, Inc. (SDGR) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Schrodinger, Inc. (SDGR) delivered earnings and revenue surprises of -68.97% and -1.38%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

The Zacks Analyst Blog Highlights: Avnet, CACI International, Schrodinger and GrowGeneration

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Avnet, CACI International, Schrodinger and GrowGeneration

Is a Surprise Coming for Schrodinger (SDGR) This Earnings Season?

by Zacks Equity Research

Schrodinger (SDGR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.